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Predicting disease outcome after the diagnosis of breast 
cancer, which is important for the choice of treatment of 
women diagnosed with this malignancy, remains a major 
challenge. Over the past decade there has been an 
increas  ing awareness of the power of genetic prediction, 
which is now beginning to provide some information that 
may be useful in the assessment of disease outcome. As 
an example, several reports in the literature indicate that 
genetic signatures are potentially useful approaches for 
prognostication. A major impediment to rapid progress 
in the identiﬁ  cation of genetic determinants of outcome 
has been, and continues to be, our limited ability to assess 
gene-gene and gene-environment interactions. Never  the-
less, inroads into understanding gene-gene interactions 
are being made due, in part, to a better appreciation of 
molecular pathway analysis. Particularly attractive targets 
of study have been genetic polymorphisms in genes 
associated with the repair of DNA damage and those 
involved in cell cycle control since an inability to tightly 
regulate either of these two processes is likely to result in 
a less than optimal outcome.
In the report by Schimdt and colleagues [1] the gene-
gene interaction between the cell cycle checkpoint 
control gene P53 and its negative regulator MDM2 has 
been examined in a large group of women diagnosed with 
breast cancer to determine whether two single nucleo  tide 
polymorphisms (SNPs), R72P in P53 (rs1042522) and 
MDM2-309 (rs2279744), could be asso  ciated with disease 
outcome. Th  is is not the ﬁ   rst study to examine the 
relationship between the tumour suppressor gene P53 
and MDM2, but it is one of the ﬁ  rst to investigate the 
relationship between polymorphisms in these genes and 
disease outcome as opposed to breast cancer risk. Th  e 
importance of the two SNPs lies in their functional 
consequence. R72 is reported to have a 15-fold greater 
capacity to induce apoptosis than P72 [2] and the MDM2
polymorphism has been shown to be associated with 
deﬁ  ciencies in the P53 response pathway [3].
Studies examining the relationship between R72P and 
MDM2-309 and cancer risk have been somewhat 
inconsistent, but many larger studies examining common 
malignancies (including breast cancer) are converging 
towards the notion that neither SNP appears to be 
associated with the risk of developing disease [4-8]. Th  ese 
results are in contrast, however, to investigations into 
cancers developing in patients diagnosed with germline 
P53 mutations, where both R72P and MDM2-309 SNPs 
do appear to be associated with diﬀ  erences in the age at 
which disease is diagnosed [3,9,10]. Th  is is perhaps not 
surprising as loss of P53 will underlie subsequent events 
associated with tumour development in this setting.
Th   e pooled analysis presented by Schmidt and 
colleagues [1] of four studies, three hospital- and one 
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Genetic diff  erences between individuals have been 
predicted to account for disparate outcomes in 
patients diagnosed with cancer. The search for genetic 
determinants has been ongoing for a considerable 
amount of time and it is only now that insights have 
been gained into which polymorphisms are most 
likely to be important in determining not only disease 
likelihood but also outcome. The quest to be able to 
accurately predict patient outcomes in breast cancer 
may now be a step closer as increased sample size is 
leading to more robust statistical analysis and a better 
understanding of molecular mechanisms of disease are 
forthcoming.
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provided suﬃ   cient power to detect whether or not there 
were any associations between the combined polymor-
phisms and disease outcome. Th  e results revealed that 
there is an association between the two SNPs and breast 
cancer outcome, suggesting that they could be used as 
potential markers to stratify patients into diﬀ  erent risk 
groups. Nevertheless, even with this large number of 
patients only 26 were homozygous for both variants, 
thereby making it impossible to quantify statistically the 
stron gest  eﬀ  ect. Th   is emphasizes the necessity of acquir-
ing large numbers of patients for genetic studies since 
smaller ones run the risk of having insuﬃ   cient power to 
detect these types of eﬀ  ect. Th   e magnitude of the eﬀ  ect, 
however, remains relatively small (with an 11% diﬀ  erence) 
and emphasises the point that these two markers account 
for only some of the diﬀ  erences between patients with 
good or poor survival.
Previously, Schmidt and colleagues [8] had demon  stra-
ted for breast cancer that neither R72P nor MDM2-309 
was associated with the risk of developing disease, which 
was supported by several other larger studies [4-7]. 
Placing this in context, the results of Schmidt and 
colleagues [1] are signiﬁ  cant as they indicate that R72P 
and  MDM2-309 act as aﬀ  ect modiﬁ  ers as opposed to 
being causal. If R72P and MDM2-309 are indeed aﬀ  ect 
modiﬁ  ers, then further studies in diﬀ  erent populations 
should yield similar results as the eﬀ  ects of the two SNPs 
would be predicted to be similar in diverse groups of 
patients. In support of this, the results are consistent with 
a report by Do and colleagues [11], who identiﬁ  ed that 
both polymorphisms also act as disease modiﬁ  ers  in 
lymphoblastic leukaemia.
Since the advent of gene expression array technology, it 
is now well recognised that there are multiple subgroups 
of breast cancer that can be characterised not only by 
their histopathology but also by gene expression proﬁ  ling 
and that these diﬀ   erences are correlated with disease 
survival [12-14]. In relation to R72P and MDM2-309, it 
would be predicted that these two SNPs, acting as disease 
modiﬁ  ers, are likely to remain associated with survival 
even in diﬀ  erent subgroups of patients as they would still 
remain aﬀ  ect-modiﬁ   ers and continue to contribute to 
disease progression irrespective of the molecular proﬁ  le 
of the tumour.
Finally, this study and those that have preceded it raise 
important points in relation to the choice of disease in 
which to examine polymorphisms in two key regulators 
of cell cycle checkpoint control. If one of the primary 
molecular alterations involves P53, then it is to be 
expected that diﬀ  erences in the remaining wild-type P53 
allele (or its downstream partners) will be inﬂ  uenced by 
intrinsic functional polymorphisms, which are likely to 
correlate with the age at disease diagnosis. If P53 is not 
involved in a disease’s initiation but in its progression, 
then it is more prone to be associated with diﬀ  erences in 
prognosis. Th   e report by Schmidt and colleagues [1] has 
signiﬁ   cantly contributed to our understanding of risk 
recurrence in patients diagnosed with breast cancer. It is 
to be expected that with larger, more deﬁ  nitive studies, 
more precise information about the role of R72P and 
MDM2-309 in disease outcome will be forthcoming.
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